BSE filing, NSE: ENNATURE. Summary written from the filing by ALFA Finder's alert engine.
Ennature Bio Pharma Ltd: key numbers
- Share price
- ₹239.15
- Market cap
- ₹534.3 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹0.00 Cr
- Promoter holding
- 59.63%
- FII holding
- 2.44%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ennature Bio Pharma Ltd
All →Ennature Bio Pharma Capital Structure Change
Ennature Bio Pharma listed its equity shares on NSE and BSE on 4 November 2026. The company brings its API, biopolymer and nutraceutical businesses to public markets.
Other board meeting date announcements
All →Cochin Minerals & Rutile Board Meeting Date
Cochin Minerals & Rutile will hold a board meeting on 12 November 2026 to consider unaudited results for the quarter and half year ended 30 September 2026. This is a future-dated board meeting notice.
Shreevatsaa Finance & Leasing Board Meeting Date
Shree Vatsaa will hold a board meeting on 14 November 2026 to consider unaudited quarterly and half-yearly results. Trading window stays closed until 48 hours after declaration.
Multipurpose Trading & Agencies Board Meeting Date
Multipurpose Trading and Agencies Limited has scheduled a board meeting for November 14, 2026, to consider unaudited financial results for the quarter and half-year ended September 30, 2026. The filing is a prior intimation only, with no results attached.
Travel Food Services Board Meeting Date
Travel Food Services will hold a board meeting on 12 November 2026 to approve unaudited quarterly and half-year results. Trading window stays closed until 14 November.
Shree Balaji (Mala) Textiles Board Meeting Date
Shree Balaji (Mala) Textiles will hold a board meeting on 12 November 2026 to approve half-year unaudited standalone results. The trading window stays closed until 14 November 2026.
Incredible Industries Board Meeting Date
Incredible Industries Ltd intimated BSE of a board meeting on 13 November 2026 to consider unaudited financial results for the quarter and half year ended 30 September 2026. The letter also notes the trading window closure from 1 October 2026 and contains no figures.